智通财经APP获悉,今日(1月15日),中国国家药监局药品审评中心(CDE)官网公示,由赛诺菲(Sanofi)(SNY.US)申报的1类新药itepekimab注射液获批临床,拟适用于治疗慢性鼻窦炎不伴鼻息肉(CRSsNP)患者。公开资料显示,这是一款靶向IL33的单克隆抗体,由赛诺菲与再生元(Regeneron)(REGN.US)合作开发。该产品此前已经在中国获得多项临床试验默示许可,适应症包括...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.